Organization (Industry)
NATERA, INC.
ClinicalTrials.gov lists NATERA, INC. as lead sponsor of 36 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 16 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 14 in 2026 and about 10 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 16 already registered with a 2026 start date: at the cutoff, 4 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.
This page covers NATERA, INC.: 36 lead-sponsored trials and 4 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (62)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Colorectal Neoplasms | 16 |
| Breast Neoplasms | 9 |
| Down Syndrome | 9 |
| Heart Defects, Congenital | 9 |
| Intellectual Disability | 9 |
Showing 5 of 62 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 16 |
| 2025 | 8 |
| 2024 | 5 |
| 2023 | 5 |
| 2022 | 9 |
| 2021 | 13 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 1 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 31% hit target (n=16) | 55% on time (n=11) |
Journals published in (67)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 12 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 11 |
| American journal of obstetrics and gynecology | 8 |
| Transplantation | 8 |
| Obstetrics and gynecology | 7 |
Showing 5 of 67 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 132 | 69 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 2,306,113,000 | -208,160,000 | 624,110,000 |
| 2024 | 1,696,911,000 | -190,426,000 | 404,138,000 |
| 2023 | 1,082,571,000 | -434,801,000 | 320,678,000 |
| 2022 | 820,222,000 | -547,799,000 | 316,415,000 |
| 2021 | 625,486,000 | -471,716,000 | 264,208,000 |
| 2020 | 391,005,000 | -229,743,000 | 100,035,000 |
| 2019 | 302,328,000 | -124,827,000 | 51,357,000 |
| 2018 | 257,654,000 | -128,154,000 | 51,355,000 |
| 2017 | 209,625,000 | -137,628,000 | 50,064,000 |
| 2016 | 212,512,000 | -100,327,000 | 41,862,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (24)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-12-10 | Follow-on offering | 464,222,328 | Edgar offerings |
| 2025-12-05 | Follow-on offering | 461,352,058 | Edgar offerings |
| 2025-12-04 | Other financing | not disclosed | Sec extracted |
| 2024-07-19 | Debt financing | not disclosed | Sec extracted |
| 2023-09-07 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 24 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| NATERA INC. | San Carlos, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 64.2% | not disclosed |
Organization relationships (32)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Montefiore Medical Center | Co sponsors trial with | 2 |
| Roche (Switzerland) | Co sponsors trial with | 2 |
| George Washington University | Co sponsors trial with | 2 |
| Columbia University | Co sponsors trial with | 2 |
| Foresight Diagnostics, Inc. | Co sponsors trial with | 2 |
Showing 5 of 32 relationships.
Latest dated events (234)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 234 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| NATERA, INC. | Certificate of accreditation | Active |
| NATERA,INC | Certificate of registration | Active |
| NATERA, INC | Certificate of registration | Active |
Biomarker capability evidence (205)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| Diagnostics manufacturer | FDA-authorized companion diagnostic | |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| BCL2 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 205 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, active development programs, approved assets, fda warning letters, fda untitled letters, fda recalls, fda import refusals, and biomarkers this organization publishes on.